Craft

Cipla

Stock Price

₹1.5 K

2024-10-29

Market Capitalization

₹1.2 T

2024-10-29

Revenue

₹254.5 B

FY, 2024

Cipla Summary

Company Summary

Overview
Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products. It offers treatments for respiratory, oncology, cardiovascular, anti-infective, urology, and central nervous system conditions, along with active pharmaceutical ingredients. The company operates in the pharmaceutical and healthcare sectors.
Type
Public
Status
Active
Founded
1935
HQ
Mumbai, IN | view all locations
Website
https://www.cipla.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Umang Vohra

    Umang Vohra, Managing Director & Global Chief Executive Officer

  • Y. K. Hamied

    Y. K. Hamied, Non-Executive Chairman

  • Ashish Adukia

    Ashish Adukia, Global Chief Financial Officer

  • Raju Mistry

    Raju Mistry, Global Chief People Officer

Operating MetricsView all

Markets

78
8.2%

FY, 2024

Drug Master Files Filed (Emerging Markets)

426
3.9%

FY, 2024

Drug Master Files Filed (India)

3
25.0%

FY, 2024

LocationsView all

22 locations detected

  • Mumbai, MH HQ

    India

    Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel

  • Central Islip, NY

    United States

    550 S Research Pl

  • Warren, NJ

    United States

    10 Independence Blvd #300

  • Melbourne, VIC

    Australia

    Level 1, 132 - 136 Albert Road

  • Antwerpen, Vlaams Gewest

    Belgium

    De Keyserlei 58 - 60 B19

  • São Paulo, SP

    Brazil

    Estrada da Lagoinha, 489 – Blocos 1 e 2 – da Lagoa

and 16 others

Cipla Financials

Summary Financials

Revenue (Q3, 2025)
₹69.6B
Gross profit (Q3, 2025)
₹50.3B
Net income (Q3, 2025)
₹15.8B
Cash (Q2, 2025)
₹9.2B
EBIT (Q3, 2025)
₹19.3B
Enterprise value
$1.2T

Footer menu